Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C20H31NO2S.C6H8O7 |
| Molecular Weight | 541.654 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CC(O)(CC(O)=O)C(O)=O.O=C(OCCN1CCCCCC1)C(C2CCCCC2)C3=CSC=C3
InChI
InChIKey=XMGJGSKRRWXOIF-UHFFFAOYSA-N
InChI=1S/C20H31NO2S.C6H8O7/c22-20(23-14-13-21-11-6-1-2-7-12-21)19(18-10-15-24-16-18)17-8-4-3-5-9-17;7-3(8)1-6(13,5(11)12)2-4(9)10/h10,15-17,19H,1-9,11-14H2;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
Cetiedil is effective potassium channel blocker used as a peripheral vasodilator to treat patients with painful crises in sickle cell anemia and pain in the extremities caused by an arterial disease. Known pharmacological properties of the drug include vascular smooth muscle relaxation, inhibition of phosphodiesterase with the consequent increase in circulating cyclic AMP concentration, blockade of the effect of bradykinin and serotonin, analgesia, inhibition of platelet aggregation and the decrease of plasma and blood viscosity and plasma fibrinogen level. The antisickling effect of cetiedil is explained mainly in the light of the changes it induces in the activities of membrane-bound ATPases and the permeability properties of the erythrocyte membrane to cations and anions.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Synthesis and structure-activity relationships of cetiedil analogues as blockers of the Ca(2+)-activated K+ permeability of erythrocytes. | 2001 Sep 27 |
|
| Inhibition of the antigen-induced activation of RBL-2H3 cells by cetiedil and some of its analogues. | 2004 Jan 12 |
|
| Pharmacology of the human red cell voltage-dependent cation channel; Part I. Activation by clotrimazole and analogues. | 2004 May-Jun |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29707
Created by
admin on Fri Dec 15 17:40:24 GMT 2023 , Edited by admin on Fri Dec 15 17:40:24 GMT 2023
|
||
|
FDA ORPHAN DRUG |
31488
Created by
admin on Fri Dec 15 17:40:24 GMT 2023 , Edited by admin on Fri Dec 15 17:40:24 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
16286-69-4
Created by
admin on Fri Dec 15 17:40:24 GMT 2023 , Edited by admin on Fri Dec 15 17:40:24 GMT 2023
|
PRIMARY | |||
|
CHEMBL419380
Created by
admin on Fri Dec 15 17:40:24 GMT 2023 , Edited by admin on Fri Dec 15 17:40:24 GMT 2023
|
PRIMARY | |||
|
66383
Created by
admin on Fri Dec 15 17:40:24 GMT 2023 , Edited by admin on Fri Dec 15 17:40:24 GMT 2023
|
PRIMARY | |||
|
m3289
Created by
admin on Fri Dec 15 17:40:24 GMT 2023 , Edited by admin on Fri Dec 15 17:40:24 GMT 2023
|
PRIMARY | Merck Index | ||
|
236204
Created by
admin on Fri Dec 15 17:40:24 GMT 2023 , Edited by admin on Fri Dec 15 17:40:24 GMT 2023
|
PRIMARY | RxNorm | ||
|
DTXSID20936756
Created by
admin on Fri Dec 15 17:40:24 GMT 2023 , Edited by admin on Fri Dec 15 17:40:24 GMT 2023
|
PRIMARY | |||
|
IE65P4OE02
Created by
admin on Fri Dec 15 17:40:24 GMT 2023 , Edited by admin on Fri Dec 15 17:40:24 GMT 2023
|
PRIMARY | |||
|
C79585
Created by
admin on Fri Dec 15 17:40:24 GMT 2023 , Edited by admin on Fri Dec 15 17:40:24 GMT 2023
|
PRIMARY | |||
|
240-381-2
Created by
admin on Fri Dec 15 17:40:24 GMT 2023 , Edited by admin on Fri Dec 15 17:40:24 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
